Literature DB >> 27694993

Ultra-rare disruptive and damaging mutations influence educational attainment in the general population.

Andrea Ganna1,2,3,4, Giulio Genovese2,3,5, Daniel P Howrigan1,2,3, Andrea Byrnes1,2,3, Mitja Kurki1,2,3,6, Seyedeh M Zekavat2,7, Christopher W Whelan2,3,5, Mart Kals8,9, Michel G Nivard10, Alex Bloemendal1,2,3, Jonathan M Bloom1,2,3, Jacqueline I Goldstein1,2,3, Timothy Poterba1,2,3, Cotton Seed1,2,3, Robert E Handsaker2,3,5, Pradeep Natarajan2,7, Reedik Mägi8, Diane Gage3, Elise B Robinson1,2,3, Andres Metspalu8, Veikko Salomaa11, Jaana Suvisaari11, Shaun M Purcell12,13, Pamela Sklar12,13, Sekar Kathiresan2,7, Mark J Daly1,2,3, Steven A McCarroll2,3,5, Patrick F Sullivan4,14, Aarno Palotie1,3,6, Tõnu Esko2,8, Christina Hultman4, Benjamin M Neale1,2,3.   

Abstract

Disruptive, damaging ultra-rare variants in highly constrained genes are enriched in individuals with neurodevelopmental disorders. In the general population, this class of variants was associated with a decrease in years of education (YOE). This effect was stronger among highly brain-expressed genes and explained more YOE variance than pathogenic copy number variation but less than common variants. Disruptive, damaging ultra-rare variants in highly constrained genes influence the determinants of YOE in the general population.

Entities:  

Mesh:

Year:  2016        PMID: 27694993      PMCID: PMC5127781          DOI: 10.1038/nn.4404

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


Educational attainment, measured by the highest number of years of education (YOE) attained, is a complex trait influenced by public policy [1], economic resources[2] and many heritable traits, including cognitive abilities and behavior [3]. Importantly, YOE is positively associated with healthy behaviors and lower rates of chronic diseases [4]. Genome-wide association study (GWAS) meta-analyses have identified 162 genome-wide significant loci for YOE [5]. The additive heritability of YOE explained by common genetics variants has been estimated at 21% (95% confidence intervals [CI] 11-31%) [6], which is approximately half of the total heritability estimated from twin studies (40%; 95% C.I. 35-44%) [7]. It has been hypothesized that rare to ultra-rare exonic variants might account for some of the heritability currently not captured by GWAS [8]. Recent studies of intellectual disability, autism and schizophrenia have shed light on the impact of de novo and ultra-rare variants (URVs: variants that are observed only once (singletons) in the study and not observed in 60,706 exomes sequenced in the Exome Aggregation Consortium (ExAC) [9]) on the genetic architecture of these disorders [10-12], showing a specific enrichment in highly constrained (HC: genes intolerant to loss-of-function or missense mutations, i.e. having a probability of being loss_of_function intolerant (pLI) > 0.9). Moreover, emerging evidence suggests that de novo loss-of-function mutations are associated with reduced adaptive functioning in individuals without diagnosis of autism[13]. We tested the hypothesis that a burden of URVs in HC genes is associated with YOE in 14,133 individuals participating in four studies from three Northern European countries: Sweden, Estonia and Finland. Of these, 5,047 individuals have been diagnosed with schizophrenia. The average numbers of YOE were 13.1, 13.6, and 11.8 in Swedish, Estonian, and Finnish participants, respectively. These differences are partially explained by different age and sex distributions, as well as by different methods used to measure educational attainment (). We observed lower YOE among men (12.8 vs. 13.2 years, P-value=4.8×10−12) and older individuals (0.8 month less of education for each additional year of age, P-value < 1×10−15) (. We developed a new software package called Hail to very efficiently perform quality control, annotation and analysis of large-scale sequencing data (Online Methods). We identified URVs in HC genes using whole exome sequencing (WES) data (N. individuals=11,431) and protein coding regions in high-coverage whole genome sequencing (WGS) data (N. individuals=2,702). The primary reason to focus on URVs in HC genes is to maximize the expected deleteriousness of the variants included (due to purifying selection). Within the set of URVs in HC genes we defined variants that were: (1) disruptive: putative loss-of-function variants including premature stop codons, essential splice site mutations and frameshift indels; (2) damaging: missense variants classified as damaging by seven different in silico prediction algorithms (Online Methods) and (3) negative control: synonymous variants not predicted to change the encoded protein. We observed one or more of such mutations in 25%, 24% and 78% of individuals, respectively (). Principal components of genetic data showed that individuals within each study were of similar ancestry (). On average (), we observed a 3.1 months reduction in YOE for each disruptive mutation (95% CI: −4.3,-2.0; P-value=3.3×10−8), and similar effect for damaging mutations (2.9 months less YOE; 95% CI: −4.1,-1.7; P-value=1.3×10−6). Furthermore, each additional disruptive mutation on average reduced the chance of going to college by 14% (odds ratio=0.86; 95% CI: 0.78,0.95; P-value=0.0017). These results were consistent when using a mixed linear model approach to correct for population stratification in the Finnish and Estonian samples with WGS data (2.4 months less YOE; 95% CI: −4.3, −0.95; P-value= 0.014, N=2,702). The negative association between URVs and YOE remained consistent when we examined the control cohort and schizophrenia case cohort separately (). Furthermore, the effect remained consistent when excluding individuals diagnosed with a neurodevelopmental disorder (i.e. schizophrenia, bipolar disorder, autism, mental retardation and Asperger's syndrome), as identified via linkage with the Swedish national inpatient registry (). We did not observe any significant association when we restricted our analysis to synonymous variants in HC genes (P-value=0.62) or disruptive mutations in unconstrained genes (P-value=0.73). We used gene-expression data to determine whether restricting to genes enriched for brain expression concentrated our URVs burden signal. Specifically, we used the Genotype-Tissue Expression consortium data [14] to identify the 20% top brain-expressed HC genes. The intersection between HC and brain-expressed genes (N. genes=683 and 313 for disruptive and damaging URVs, respectively) more than doubled the impact on YOE (6.5 less months of YOE per each additional disruptive variant; 95% CI: −9.6,-3.4; P-value=3.4×10−5; ). When using increasingly liberal thresholds for defining genes enriched for brain-expression, we saw a consistent decrease in the association (). The association was not significant when considering non brain-enriched HC genes or all brain-enriched genes (P-value > 0.05). We further examined a subset of genes for which basal gene-expression was at least two fold higher in the brain compared to other tissues (brain-enriched HC genes; ). Although, the impact on YOE was higher for brain-enriched HC genes than non brain-enriched HC genes, the signal was specific to disruptive variants. Overall, this approach was less effective in identifying a HC gene subset impacting YOE. To place disruptive and damaging URVs into context, we also examined the impact of previously reported genetic influences on YOE, including a polygenic score from common variants [5], runs of homozygosity [15] and a burden of rare pathogenic copy number variants (CNVs) [16]. We sought to establish if these different forms of genetic variation act independently on YOE. For this purpose we defined four scores: (1) a polygenic score including all the independent single nucleotide polymorphisms (SNPs) with P-value for association with YOE < 1 (as this threshold has been shown to maximize variance explained in YOE) in a large GWAS consortia of YOE [5] (2) the summed length of all runs of homozygosity (3) burden of disruptive and damaging URVs in HC genes and (4) burden of self-curated list of pathogenic CNVs from the literature (). The polygenic score was only calculated in the Swedish samples (N=10,644), since the other three studies were included in the original GWAS of YOE. We first explored the association between each genetic score and YOE separately. The strongest change in YOE was observed among CNV carriers (−7.6 months less YOE; 95% CI: −13.7,-1.5; P-value= 0.015). However, these events were rare in the population (161 carriers among 11,999 individuals with CNV measured). We then fit the four normalized scores in the same regression model to assess the relative contribution of each genetic class to YOE. All four scores were independently associated with YOE (). The polygenic score showed the strongest association in standard deviations from the mean, explaining the largest proportion of the variability in YOE (2.9% vs 0.4% for the ultra-rare variants, 0.2% for runs of homozygosity and 0.1% for pathogenic CNVs). We further evaluated whether the association between the polygenic score and YOE changes in individuals with and without disruptive or damaging URVs or CNVs. We found that the polygenic score was more strongly associated with YOE in individuals without disruptive or damaging URVs or CNVs (8.2 vs. 6.2 more months of YOE for 1 standard deviation increase in the polygenic score; P-value for interaction=0.007, ). We sought to identify individual genes driving the observed association between disruptive and damaging URVs and YOE. Using a gene-based burden test implemented in SKAT [17], and using an exome-wide significance threshold of 1×10−6, we didn't identify any statistically significantly associated gene (). Similar results were observed when we included all variants with minor allele frequency < 0.05%, rather than only URVs (s). In this study we focused on YOE, a phenotype that is relatively easy to collect in large samples and which has a strong genetic correlation with intelligence and cognitive function [6,18]. We integrated WGS, WES and array data on more than 14,000 individuals and described the impact of URVs disrupting HC genes on YOE. This class of variants have been previously associated with autism[3] and schizophrenia[4], but the impact on YOE in the general population has not been described before. Here, for the first time, we show that disruptive and damaging URVs in HC genes are likely to affect factors underlying education attainment among individuals not diagnosed with psychiatric or neurodevelopmental disorders. Exploring the extent to which this association is mediated by cognitive-related determinants of YOE, or by other non-cognitive factors will require studies integrating detailed cognitive, psychological and personality measurements. Similar to the analyses of schizophrenia[10] and autism, the majority of the signal lies in genes highly expressed in brain. This observation does not exclude the existence of causal mutations outside this gene class, but suggests that strong acting mutations are heavily concentrated within these genes. Furthermore, we show that disruptive and damaging URVs in HC genes, common variants associated with YOE, runs of homozygosity, and pathogenic CNVs, all act on cognitive function or personality traits ultimately reflected in the educational attainment of our study participants. This effect was not simply additive. We identified a modest, but significant interaction between the polygenic score and the presence of URVs or CNVs. Whether this observation is driven by the interplay of partially overlapping pathways between common and rare variants or by genotype-phenotype heterogeneity (e.g. common and rare variants impacting different subsets of individuals) will be a matter of future investigation. We report that, on average, an additional disruptive URVs in HC genes results in a 3.1 months reduction in YOE. This effect is likely to be a mixture of variants with larger effect and variants that are not associated with YOE. The polygenic score based on common variants effect sizes estimated from a much larger cohort of 405,072 individuals explained a larger fraction of the YOE. This is not surprising, given that common variants are expected to have the largest contribution to heritable variation in most complex traits [19]. The prioritization approaches used to select variants contributing to the score from common variants and the score from rare variants are different. The former uses estimates of the association with YOE and the proportion of variance explained by the score is likely to improve once the sample size used to originate these estimates increases. The latter uses in-silico prediction of the variants’ functional effect coupled with population genetics expectations built on the mutation rate. As with the common variant score, we expect that the score based on URVs in selected gene sets will continue to improve in predictive validity of YOE as a more precise characterization of which genes and genomic regions are associated with YOE emerges. Our study could not detect disruptive or damaging mutations in a given gene as being unequivocally associated with YOE; however, as sample sizes increase, specific genes will emerge. Nevertheless, our proof-of-concept work shows that a wide range of genetic variation from URVs and CNVs to common variants influence determinants of YOE in the population.

ONLINE METHODS

Studies description and selection

In this study we used epidemiological studies with YOE and exome or whole-genome sequencing information available, no formal power calculation was done. Ethical committees in Sweden, Estonia and Finland approved all procedures and all subjects provided written informed consent (or legal guardian consent and subject assent).

Sweden-WES

A total of 12,384 blood-derived DNA samples from Swedish research participants were collected from 2005 to 2013. Psychiatric cases with a diagnosis of schizophrenia were ascertained from the Swedish National Hospital Discharge Register. The register is complete from 1987 and augmented by psychiatric data from 1973-86. It contains dates and ICD discharge diagnoses (World Health Organization, 1992) for each hospitalization, and captures the clinical diagnosis made by the attending physician. Case inclusion criteria: ≥2 hospitalizations with a discharge diagnosis of schizophrenia, both parents born in Scandinavia, and age ≥18 years. Case exclusion criteria: hospital register diagnosis of any medical or psychiatric disorder mitigating a confident diagnosis of schizophrenia as determined by expert review, and included removal of 3.4% of eligible cases due to the primacy of another psychiatric disorder (0.9%) or a general medical condition (0.3%) or uncertainties in the Hospital Discharge Register (e.g., contiguous admissions with brief total duration, 2.2%). The validity of this case definition of schizophrenia is strongly supported as described in [20]. Controls were selected at random from Swedish population registers. Control inclusion criteria: never hospitalized for schizophrenia or bipolar disorder (given evidence of genetic overlap with schizophrenia), both parents born in Scandinavia, and age ≥18 years.

Estonia-WGS

Estonian-WGS samples are the subset of the Estonian Biobank of the Estonian Genome Center at the University of Tartu [21]. It is a population-based biobank, containing almost 52,000 samples of the adult population (aged ≥18 years), which closely reflects the age, sex and geographical distribution of the Estonian population. All subjects have been recruited randomly by general practitioners or physicians in hospitals throughout the country. The participants donated blood samples for DNA, white blood cells and plasma tests and filled the Computer Assisted Personal Interview (CAPI). In total, 2,300 geographically diverse samples have whole genome sequencing data, selected randomly by county of birth.

Finnish-WES and Finnish-WGS

All of the Finnish individuals are part of the FINRISK cohort, a national survey on risk factors of chronic and non-communicable diseases in Finland [22]. The survey has been conducted every five years since 1972 in randomly selected, representative population samples from different parts of Finland. All of the samples are from FINRISK 1992, 1997, 2002 and 2007 surveys. Finnish-WES mainly includes individuals that are part of an IBD case-control study, where controls were selected to have a high IBD polygenic risk score [23]. Finnish-WGS includes schizophrenia cases and controls selected using nationwide hospital discharge registry and/or nationwide medicine reimbursement registry where all psychosis cases or psychosis medication purchases are systematically recorded. Controls were selected to have high polygenic risk score for schizophrenia [24].

Phenotype definition

We matched the original educational categories with the International Standard Classification of Education (ISCED), as described in . Thereafter we used the equivalent of United States years of schooling to obtain the YOE. Going to college was defined as having an ISCED category > 4. To remove potential bias introduced by uncompleted education, we excluded all the individuals younger than 30 years at the time of sample collection. For the Estonian and Finnish samples, we used self-report data; whereas for the Swedish sample, we obtained YOE from the national registries. YOE was approximately normally distributed.

Sequencing procedures

Estonian WGS and Finnish WGS samples have been sequenced at Broad Institute on Illumina HiSeq X Ten machines run to 20x and 30x mean coverage (150bp paired reads), respectively. Estonian samples followed a PCR-free sample preparation. Swedish-WES and Finnish-WES samples were sequenced using either the Agilent SureSelect Human All Exon Kit or the Agilent SureSelect Human All Exon v.2 Kit. Sequencing was performed at Broad institute on Illumina GAII, Illumina HiSeq2000 or Illumina HiSeq X Ten. Mean target coverage was 90x. All samples have been aligned against the GRCh37 human genome reference and BAM processing was carried out using BWA Picard. Genotype calling was done using GATK Haplotype Caller and was performed at Broad Institute for all studies.

Hail software

To overcome the growing computational challenge of learning from large genomic datasets, we utilized Hail, an open-source software framework for scalably and flexibly analyzing such data (https://github.com/broadinstitute/hail). Hail, under active development, includes support for data import/export, quality control, analysis of population structure, and methods for performing both common and rare variant association. Hail is written in Scala (a Java virtual machine language) and builds on open-source software for scalable distributed computing including Hadoop (http://hadoop.apache.org/) and Spark (http://spark.apache.org/). Hail achieves near-perfect scalability for many tasks and can run on thousands of nodes. Hail automates fault-tolerant distribution of data and compute, greatly simplifying distributed pipeline execution compared to traditional HPC job schedulers like LSF and Grid Engine. Pipelines written in Hail's high-level language typical require orders-of-magnitude fewer lines of code than comparable pipelines written in general purpose languages.

Samples and variants QC

Quality control was performed independently for each study using Hail. We excluded individuals with high proportion of chimeric reads (>5%), high contamination (>5%) or an excessive number of singletons variants not observed in ExAC (> 100 for WES and > 20,000 for WGS). We included only unrelated individuals (IBD proportion < 0.2) and those for whom the sex predicted from genetic data matched the self-reported gender. We kept only ‘PASS’ variants, as determined by The Genome Analysis Toolkit [25] Variant Quality Score Recalibration (VQSR) filter, are set to missing variants with GQ < 20 and allele balance > 0.8 or < 0.2. We further excluded variants with call rate < 0.8. In WGS data, we excluded low complexity regions as defined by Li [26]. In the burden test analysis we excluded variants with both Hardy-Weinberg equilibrium test P-value < 1×10−6 and negative inbreeding coefficient (expected heterozygosity less than observed heterozygosity).

Annotation and URVs scores definition

Annotation was performed using SnpEff 4.2 (build 2015-12-05) [27] using Ensemble gene models from database GRCh37.75. We further annotated variants with SnpSift 4.2 (build 2015-12-05) [28] using annotations from database dbNSFP 2.9 [29]. In we have provided a detailed description of the criteria used for selecting variants in each score. The set of HC genes was defined separately for disruptive and damaging variants. For disruptive and synonymous mutations we defined HC genes those having a probability of being loss_of_function intolerant (pLI) > 0.9 (N genes=3,488). For missense damaging mutation we used a missense z-score > 3.09 (N genes=1,614) [30]. Both measures have been previously described [30] and available online at ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/functional_gene_constraint. We used a version derived from The Exome Aggregation Consortium without cases of psychiatric disorders.

Principal component analysis and mixed models

We used a subset of high confidence SNPs to calculate principal components. We selected variants with minor allele frequency larger than 5%, call rate > 90%, Hardy-Weinberg equilibrium test P-value > 1×10−6 and we pruned for variants in linkage disequilibrium using plink with command line ‘--indep 50 5 2’. We used a similar approach to filter variants used to generate the genetic relationship matrix (GRM). We then fit a liner mixed model including the GRM as random effect and age, sex, year of birth, (year of birth – 1950)[2], (year of birth – 1950)[3], the number of singletons synonymous variants not in ExAC and the number of URVs in HC genes as fixed effects.

Association between URVs and educational attainment

We fit a linear regression model where the dependent variable was YOE and the independent predictors were: age, sex, year of birth, (year of birth – 1950)[2], (year of birth – 1950)[3], the 10 first principal components, the number of singletons synonymous variants not in ExAC, schizophrenia status (only in studies including schizophrenic patients) and the URV score (count of disruptive, damaging or synonymous URVs). We adjust for the number of all ultra-rare synonymous variants to correct for potential technical artifacts. We observed similar results when adjusting for number of ultra-rare synonymous variants + number of ultra-rare disruptive (or damaging) variants in HC genes.

Brain-expressed and brain-enriched HC genes analysis

Using the Genotype-Tissue Expression consortia (GTEx) data [14], we ranked gene-expression levels (in RPKM) in brain tissues and defined the top 20% HC genes as “brain-expressed” (N. genes=683 and 313 for disruptive and damaging, respectively). Conversely, we defined “non brain expressed” the bottom 20% of the HC genes (N. genes=683 and 313 for disruptive and damaging, respectively). We also compute estimated fold-change in the brain as follows. Suppose samples 1, 2, ..., N are brain samples and samples (N are the samples from other tissues. Denote with xij the expression of gene j and sample i, in reads per kilobase of transcript per million (RPKM). We compute fold-change (FC): We label the genes j, such that FC > 2 as “brain-enriched genes” and FC < 0.5 as “non-brain-enriched genes”. The number of brain-enriched HC genes was 447 and 287 for disruptive and damaging mutations, respectively. The number of non brain-enriched HC genes was 2,225 and 935 for disruptive and damaging mutations, respectively.

Polygenic score, CNVs and runs homozygosity

The polygenic score for YOE was obtained from array data in the Swedish WES study (quality control for the array data have been previously described [20]) and directly from WGS data in the Finnish-WGS and Estonian-WGS studies. We included all the independent markers with P-value < 1 in largest GWAS of educational attainment [5] and obtained the polygenic score as weighted sum of risk alleles using the --score command in Plink [31]. CNVs for the Swedish WES study were called as part of a separate project [32] using a composite pipeline comprising the CNV callers PennCNV, iPattern, Birdsuite and C-Score organized into component pipelines. We considered only rare CNVs by filtering out all CNVs that present at ≥ 1% allele frequency. CNVs < 20kb or having fewer than 10 probes were also excluded. We used the plink --cnv-intersect function with a value of 0.5 to determine the overlap between detected CNVs and the list of pathogenic CNVs reported in . CNVs in Finnish WGS and Estonian WGS were genotyped according to the methods described in [33] and implemented in Genome STRiP 2.0. Briefly, read depth information was collected from WGS data, excluding regions of the genome that are not uniquely alignable or have low sequence complexity, and adjusted for GC content bias. Each CNV reported in was directly genotyped using Genome STRiP's genotyping module, which examines the read depth across all samples and fits a constrained Gaussian mixture model with components representing each possible diploid copy number and sample-specific variance terms to account for differences in sequencing depth. The summed runs of homozygosity were determined using the same pipeline described in [15]. Specifically we used plink with command line ‘--homozyg --homozyg-window-snp 35 --homozyg-snp 35 --homozyg-kb 1500 --homozyg-gap 1000 --homozyg-density 250 --homozyg-window-missing 5 --homozyg-window-het 1’.

Gene-based burden test

We first extracted from each dataset variants falling within UCSC known genes and merged the four datasets using plink. If a variant was not present in all cohorts, we forced it as homozygous reference across the remaining cohorts (using “--fill-missing-a2” option in plink). We then computed principal components for the combined dataset after further merging with 1000 Genomes project samples as described in (Genovese et al, jointly submitted). To test the hypotheses that disruptive URVs in individual genes were associated with YOE and college status, we performed a burden test [34] using the SKAT software [35] using default parameters (method=davies, impute.method=bestguess, r.corr=1.0), adjusting for age, sex, year of birth, (year of birth – 1950)[2], (year of birth – 1950)[3], the first 10 principal components, schizophrenia status and number of URVs identified in coding regions. We used a python wrapper to run the SKAT software (available at https://github.com/freeseek/gwaspipeline).
  31 in total

1.  Genome sequencing identifies major causes of severe intellectual disability.

Authors:  Christian Gilissen; Jayne Y Hehir-Kwa; Djie Tjwan Thung; Maartje van de Vorst; Bregje W M van Bon; Marjolein H Willemsen; Michael Kwint; Irene M Janssen; Alexander Hoischen; Annette Schenck; Richard Leach; Robert Klein; Rick Tearle; Tan Bo; Rolph Pfundt; Helger G Yntema; Bert B A de Vries; Tjitske Kleefstra; Han G Brunner; Lisenka E L M Vissers; Joris A Veltman
Journal:  Nature       Date:  2014-06-04       Impact factor: 49.962

Review 2.  What is effective intervention?--using theories of health promotion.

Authors:  Karen Davies
Journal:  Br J Nurs       Date:  2006 Mar 9-22

3.  dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations.

Authors:  Xiaoming Liu; Xueqiu Jian; Eric Boerwinkle
Journal:  Hum Mutat       Date:  2013-07-10       Impact factor: 4.878

4.  Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects.

Authors:  Christian R Marshall; Daniel P Howrigan; Daniele Merico; Bhooma Thiruvahindrapuram; Wenting Wu; Douglas S Greer; Danny Antaki; Aniket Shetty; Peter A Holmans; Dalila Pinto; Madhusudan Gujral; William M Brandler; Dheeraj Malhotra; Zhouzhi Wang; Karin V Fuentes Fajarado; Michelle S Maile; Stephan Ripke; Ingrid Agartz; Margot Albus; Madeline Alexander; Farooq Amin; Joshua Atkins; Silviu A Bacanu; Richard A Belliveau; Sarah E Bergen; Marcelo Bertalan; Elizabeth Bevilacqua; Tim B Bigdeli; Donald W Black; Richard Bruggeman; Nancy G Buccola; Randy L Buckner; Brendan Bulik-Sullivan; William Byerley; Wiepke Cahn; Guiqing Cai; Murray J Cairns; Dominique Campion; Rita M Cantor; Vaughan J Carr; Noa Carrera; Stanley V Catts; Kimberley D Chambert; Wei Cheng; C Robert Cloninger; David Cohen; Paul Cormican; Nick Craddock; Benedicto Crespo-Facorro; James J Crowley; David Curtis; Michael Davidson; Kenneth L Davis; Franziska Degenhardt; Jurgen Del Favero; Lynn E DeLisi; Dimitris Dikeos; Timothy Dinan; Srdjan Djurovic; Gary Donohoe; Elodie Drapeau; Jubao Duan; Frank Dudbridge; Peter Eichhammer; Johan Eriksson; Valentina Escott-Price; Laurent Essioux; Ayman H Fanous; Kai-How Farh; Martilias S Farrell; Josef Frank; Lude Franke; Robert Freedman; Nelson B Freimer; Joseph I Friedman; Andreas J Forstner; Menachem Fromer; Giulio Genovese; Lyudmila Georgieva; Elliot S Gershon; Ina Giegling; Paola Giusti-Rodríguez; Stephanie Godard; Jacqueline I Goldstein; Jacob Gratten; Lieuwe de Haan; Marian L Hamshere; Mark Hansen; Thomas Hansen; Vahram Haroutunian; Annette M Hartmann; Frans A Henskens; Stefan Herms; Joel N Hirschhorn; Per Hoffmann; Andrea Hofman; Hailiang Huang; Masashi Ikeda; Inge Joa; Anna K Kähler; René S Kahn; Luba Kalaydjieva; Juha Karjalainen; David Kavanagh; Matthew C Keller; Brian J Kelly; James L Kennedy; Yunjung Kim; James A Knowles; Bettina Konte; Claudine Laurent; Phil Lee; S Hong Lee; Sophie E Legge; Bernard Lerer; Deborah L Levy; Kung-Yee Liang; Jeffrey Lieberman; Jouko Lönnqvist; Carmel M Loughland; Patrik K E Magnusson; Brion S Maher; Wolfgang Maier; Jacques Mallet; Manuel Mattheisen; Morten Mattingsdal; Robert W McCarley; Colm McDonald; Andrew M McIntosh; Sandra Meier; Carin J Meijer; Ingrid Melle; Raquelle I Mesholam-Gately; Andres Metspalu; Patricia T Michie; Lili Milani; Vihra Milanova; Younes Mokrab; Derek W Morris; Bertram Müller-Myhsok; Kieran C Murphy; Robin M Murray; Inez Myin-Germeys; Igor Nenadic; Deborah A Nertney; Gerald Nestadt; Kristin K Nicodemus; Laura Nisenbaum; Annelie Nordin; Eadbhard O'Callaghan; Colm O'Dushlaine; Sang-Yun Oh; Ann Olincy; Line Olsen; F Anthony O'Neill; Jim Van Os; Christos Pantelis; George N Papadimitriou; Elena Parkhomenko; Michele T Pato; Tiina Paunio; Diana O Perkins; Tune H Pers; Olli Pietiläinen; Jonathan Pimm; Andrew J Pocklington; John Powell; Alkes Price; Ann E Pulver; Shaun M Purcell; Digby Quested; Henrik B Rasmussen; Abraham Reichenberg; Mark A Reimers; Alexander L Richards; Joshua L Roffman; Panos Roussos; Douglas M Ruderfer; Veikko Salomaa; Alan R Sanders; Adam Savitz; Ulrich Schall; Thomas G Schulze; Sibylle G Schwab; Edward M Scolnick; Rodney J Scott; Larry J Seidman; Jianxin Shi; Jeremy M Silverman; Jordan W Smoller; Erik Söderman; Chris C A Spencer; Eli A Stahl; Eric Strengman; Jana Strohmaier; T Scott Stroup; Jaana Suvisaari; Dragan M Svrakic; Jin P Szatkiewicz; Srinivas Thirumalai; Paul A Tooney; Juha Veijola; Peter M Visscher; John Waddington; Dermot Walsh; Bradley T Webb; Mark Weiser; Dieter B Wildenauer; Nigel M Williams; Stephanie Williams; Stephanie H Witt; Aaron R Wolen; Brandon K Wormley; Naomi R Wray; Jing Qin Wu; Clement C Zai; Rolf Adolfsson; Ole A Andreassen; Douglas H R Blackwood; Elvira Bramon; Joseph D Buxbaum; Sven Cichon; David A Collier; Aiden Corvin; Mark J Daly; Ariel Darvasi; Enrico Domenici; Tõnu Esko; Pablo V Gejman; Michael Gill; Hugh Gurling; Christina M Hultman; Nakao Iwata; Assen V Jablensky; Erik G Jönsson; Kenneth S Kendler; George Kirov; Jo Knight; Douglas F Levinson; Qingqin S Li; Steven A McCarroll; Andrew McQuillin; Jennifer L Moran; Bryan J Mowry; Markus M Nöthen; Roel A Ophoff; Michael J Owen; Aarno Palotie; Carlos N Pato; Tracey L Petryshen; Danielle Posthuma; Marcella Rietschel; Brien P Riley; Dan Rujescu; Pamela Sklar; David St Clair; James T R Walters; Thomas Werge; Patrick F Sullivan; Michael C O'Donovan; Stephen W Scherer; Benjamin M Neale; Jonathan Sebat
Journal:  Nat Genet       Date:  2016-11-21       Impact factor: 38.330

5.  Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift.

Authors:  Pablo Cingolani; Viral M Patel; Melissa Coon; Tung Nguyen; Susan J Land; Douglas M Ruden; Xiangyi Lu
Journal:  Front Genet       Date:  2012-03-15       Impact factor: 4.599

6.  Directional dominance on stature and cognition in diverse human populations.

Authors:  Peter K Joshi; Tonu Esko; Ozren Polašek; James F Wilson; Hannele Mattsson; Niina Eklund; Ilaria Gandin; Teresa Nutile; Anne U Jackson; Claudia Schurmann; Albert V Smith; Weihua Zhang; Yukinori Okada; Alena Stančáková; Jessica D Faul; Wei Zhao; Traci M Bartz; Maria Pina Concas; Nora Franceschini; Stefan Enroth; Veronique Vitart; Stella Trompet; Xiuqing Guo; Daniel I Chasman; Jeffery R O'Connel; Tanguy Corre; Suraj S Nongmaithem; Yuning Chen; Massimo Mangino; Daniela Ruggiero; Michela Traglia; Aliki-Eleni Farmaki; Tim Kacprowski; Andrew Bjonnes; Ashley van der Spek; Ying Wu; Anil K Giri; Lisa R Yanek; Lihua Wang; Edith Hofer; Cornelius A Rietveld; Olga McLeod; Marilyn C Cornelis; Cristian Pattaro; Niek Verweij; Clemens Baumbach; Abdel Abdellaoui; Helen R Warren; Dragana Vuckovic; Hao Mei; Claude Bouchard; John R B Perry; Stefania Cappellani; Saira S Mirza; Miles C Benton; Ulrich Broeckel; Sarah E Medland; Penelope A Lind; Giovanni Malerba; Alexander Drong; Loic Yengo; Lawrence F Bielak; Degui Zhi; Peter J van der Most; Daniel Shriner; Reedik Mägi; Gibran Hemani; Tugce Karaderi; Zhaoming Wang; Tian Liu; Ilja Demuth; Jing Hua Zhao; Weihua Meng; Lazaros Lataniotis; Sander W van der Laan; Jonathan P Bradfield; Andrew R Wood; Amelie Bonnefond; Tarunveer S Ahluwalia; Leanne M Hall; Erika Salvi; Seyhan Yazar; Lisbeth Carstensen; Hugoline G de Haan; Mark Abney; Uzma Afzal; Matthew A Allison; Najaf Amin; Folkert W Asselbergs; Stephan J L Bakker; R Graham Barr; Sebastian E Baumeister; Daniel J Benjamin; Sven Bergmann; Eric Boerwinkle; Erwin P Bottinger; Archie Campbell; Aravinda Chakravarti; Yingleong Chan; Stephen J Chanock; Constance Chen; Y-D Ida Chen; Francis S Collins; John Connell; Adolfo Correa; L Adrienne Cupples; George Davey Smith; Gail Davies; Marcus Dörr; Georg Ehret; Stephen B Ellis; Bjarke Feenstra; Mary F Feitosa; Ian Ford; Caroline S Fox; Timothy M Frayling; Nele Friedrich; Frank Geller; Generation Scotland; Irina Gillham-Nasenya; Omri Gottesman; Misa Graff; Francine Grodstein; Charles Gu; Chris Haley; Christopher J Hammond; Sarah E Harris; Tamara B Harris; Nicholas D Hastie; Nancy L Heard-Costa; Kauko Heikkilä; Lynne J Hocking; Georg Homuth; Jouke-Jan Hottenga; Jinyan Huang; Jennifer E Huffman; Pirro G Hysi; M Arfan Ikram; Erik Ingelsson; Anni Joensuu; Åsa Johansson; Pekka Jousilahti; J Wouter Jukema; Mika Kähönen; Yoichiro Kamatani; Stavroula Kanoni; Shona M Kerr; Nazir M Khan; Philipp Koellinger; Heikki A Koistinen; Manraj K Kooner; Michiaki Kubo; Johanna Kuusisto; Jari Lahti; Lenore J Launer; Rodney A Lea; Benjamin Lehne; Terho Lehtimäki; David C M Liewald; Lars Lind; Marie Loh; Marja-Liisa Lokki; Stephanie J London; Stephanie J Loomis; Anu Loukola; Yingchang Lu; Thomas Lumley; Annamari Lundqvist; Satu Männistö; Pedro Marques-Vidal; Corrado Masciullo; Angela Matchan; Rasika A Mathias; Koichi Matsuda; James B Meigs; Christa Meisinger; Thomas Meitinger; Cristina Menni; Frank D Mentch; Evelin Mihailov; Lili Milani; May E Montasser; Grant W Montgomery; Alanna Morrison; Richard H Myers; Rajiv Nadukuru; Pau Navarro; Mari Nelis; Markku S Nieminen; Ilja M Nolte; George T O'Connor; Adesola Ogunniyi; Sandosh Padmanabhan; Walter R Palmas; James S Pankow; Inga Patarcic; Francesca Pavani; Patricia A Peyser; Kirsi Pietilainen; Neil Poulter; Inga Prokopenko; Sarju Ralhan; Paul Redmond; Stephen S Rich; Harri Rissanen; Antonietta Robino; Lynda M Rose; Richard Rose; Cinzia Sala; Babatunde Salako; Veikko Salomaa; Antti-Pekka Sarin; Richa Saxena; Helena Schmidt; Laura J Scott; William R Scott; Bengt Sennblad; Sudha Seshadri; Peter Sever; Smeeta Shrestha; Blair H Smith; Jennifer A Smith; Nicole Soranzo; Nona Sotoodehnia; Lorraine Southam; Alice V Stanton; Maria G Stathopoulou; Konstantin Strauch; Rona J Strawbridge; Matthew J Suderman; Nikhil Tandon; Sian-Tsun Tang; Kent D Taylor; Bamidele O Tayo; Anna Maria Töglhofer; Maciej Tomaszewski; Natalia Tšernikova; Jaakko Tuomilehto; Andre G Uitterlinden; Dhananjay Vaidya; Astrid van Hylckama Vlieg; Jessica van Setten; Tuula Vasankari; Sailaja Vedantam; Efthymia Vlachopoulou; Diego Vozzi; Eero Vuoksimaa; Melanie Waldenberger; Erin B Ware; William Wentworth-Shields; John B Whitfield; Sarah Wild; Gonneke Willemsen; Chittaranjan S Yajnik; Jie Yao; Gianluigi Zaza; Xiaofeng Zhu; The BioBank Japan Project; Rany M Salem; Mads Melbye; Hans Bisgaard; Nilesh J Samani; Daniele Cusi; David A Mackey; Richard S Cooper; Philippe Froguel; Gerard Pasterkamp; Struan F A Grant; Hakon Hakonarson; Luigi Ferrucci; Robert A Scott; Andrew D Morris; Colin N A Palmer; George Dedoussis; Panos Deloukas; Lars Bertram; Ulman Lindenberger; Sonja I Berndt; Cecilia M Lindgren; Nicholas J Timpson; Anke Tönjes; Patricia B Munroe; Thorkild I A Sørensen; Charles N Rotimi; Donna K Arnett; Albertine J Oldehinkel; Sharon L R Kardia; Beverley Balkau; Giovanni Gambaro; Andrew P Morris; Johan G Eriksson; Margie J Wright; Nicholas G Martin; Steven C Hunt; John M Starr; Ian J Deary; Lyn R Griffiths; Henning Tiemeier; Nicola Pirastu; Jaakko Kaprio; Nicholas J Wareham; Louis Pérusse; James G Wilson; Giorgia Girotto; Mark J Caulfield; Olli Raitakari; Dorret I Boomsma; Christian Gieger; Pim van der Harst; Andrew A Hicks; Peter Kraft; Juha Sinisalo; Paul Knekt; Magnus Johannesson; Patrik K E Magnusson; Anders Hamsten; Reinhold Schmidt; Ingrid B Borecki; Erkki Vartiainen; Diane M Becker; Dwaipayan Bharadwaj; Karen L Mohlke; Michael Boehnke; Cornelia M van Duijn; Dharambir K Sanghera; Alexander Teumer; Eleftheria Zeggini; Andres Metspalu; Paolo Gasparini; Sheila Ulivi; Carole Ober; Daniela Toniolo; Igor Rudan; David J Porteous; Marina Ciullo; Tim D Spector; Caroline Hayward; Josée Dupuis; Ruth J F Loos; Alan F Wright; Giriraj R Chandak; Peter Vollenweider; Alan Shuldiner; Paul M Ridker; Jerome I Rotter; Naveed Sattar; Ulf Gyllensten; Kari E North; Mario Pirastu; Bruce M Psaty; David R Weir; Markku Laakso; Vilmundur Gudnason; Atsushi Takahashi; John C Chambers; Jaspal S Kooner; David P Strachan; Harry Campbell; Joel N Hirschhorn; Markus Perola
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

7.  Large multiallelic copy number variations in humans.

Authors:  Robert E Handsaker; Vanessa Van Doren; Jennifer R Berman; Giulio Genovese; Seva Kashin; Linda M Boettger; Steven A McCarroll
Journal:  Nat Genet       Date:  2015-01-26       Impact factor: 38.330

8.  A groupwise association test for rare mutations using a weighted sum statistic.

Authors:  Bo Eskerod Madsen; Sharon R Browning
Journal:  PLoS Genet       Date:  2009-02-13       Impact factor: 5.917

9.  Genome-wide association analysis identifies 13 new risk loci for schizophrenia.

Authors:  Stephan Ripke; Colm O'Dushlaine; Kimberly Chambert; Jennifer L Moran; Anna K Kähler; Susanne Akterin; Sarah E Bergen; Ann L Collins; James J Crowley; Menachem Fromer; Yunjung Kim; Sang Hong Lee; Patrik K E Magnusson; Nick Sanchez; Eli A Stahl; Stephanie Williams; Naomi R Wray; Kai Xia; Francesco Bettella; Anders D Borglum; Brendan K Bulik-Sullivan; Paul Cormican; Nick Craddock; Christiaan de Leeuw; Naser Durmishi; Michael Gill; Vera Golimbet; Marian L Hamshere; Peter Holmans; David M Hougaard; Kenneth S Kendler; Kuang Lin; Derek W Morris; Ole Mors; Preben B Mortensen; Benjamin M Neale; Francis A O'Neill; Michael J Owen; Milica Pejovic Milovancevic; Danielle Posthuma; John Powell; Alexander L Richards; Brien P Riley; Douglas Ruderfer; Dan Rujescu; Engilbert Sigurdsson; Teimuraz Silagadze; August B Smit; Hreinn Stefansson; Stacy Steinberg; Jaana Suvisaari; Sarah Tosato; Matthijs Verhage; James T Walters; Douglas F Levinson; Pablo V Gejman; Kenneth S Kendler; Claudine Laurent; Bryan J Mowry; Michael C O'Donovan; Michael J Owen; Ann E Pulver; Brien P Riley; Sibylle G Schwab; Dieter B Wildenauer; Frank Dudbridge; Peter Holmans; Jianxin Shi; Margot Albus; Madeline Alexander; Dominique Campion; David Cohen; Dimitris Dikeos; Jubao Duan; Peter Eichhammer; Stephanie Godard; Mark Hansen; F Bernard Lerer; Kung-Yee Liang; Wolfgang Maier; Jacques Mallet; Deborah A Nertney; Gerald Nestadt; Nadine Norton; Francis A O'Neill; George N Papadimitriou; Robert Ribble; Alan R Sanders; Jeremy M Silverman; Dermot Walsh; Nigel M Williams; Brandon Wormley; Maria J Arranz; Steven Bakker; Stephan Bender; Elvira Bramon; David Collier; Benedicto Crespo-Facorro; Jeremy Hall; Conrad Iyegbe; Assen Jablensky; Rene S Kahn; Luba Kalaydjieva; Stephen Lawrie; Cathryn M Lewis; Kuang Lin; Don H Linszen; Ignacio Mata; Andrew McIntosh; Robin M Murray; Roel A Ophoff; John Powell; Dan Rujescu; Jim Van Os; Muriel Walshe; Matthias Weisbrod; Durk Wiersma; Peter Donnelly; Ines Barroso; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden P Corvin; Panos Deloukas; Audrey Duncanson; Janusz Jankowski; Hugh S Markus; Christopher G Mathew; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Richard C Trembath; Ananth C Viswanathan; Nicholas W Wood; Chris C A Spencer; Gavin Band; Céline Bellenguez; Colin Freeman; Garrett Hellenthal; Eleni Giannoulatou; Matti Pirinen; Richard D Pearson; Amy Strange; Zhan Su; Damjan Vukcevic; Peter Donnelly; Cordelia Langford; Sarah E Hunt; Sarah Edkins; Rhian Gwilliam; Hannah Blackburn; Suzannah J Bumpstead; Serge Dronov; Matthew Gillman; Emma Gray; Naomi Hammond; Alagurevathi Jayakumar; Owen T McCann; Jennifer Liddle; Simon C Potter; Radhi Ravindrarajah; Michelle Ricketts; Avazeh Tashakkori-Ghanbaria; Matthew J Waller; Paul Weston; Sara Widaa; Pamela Whittaker; Ines Barroso; Panos Deloukas; Christopher G Mathew; Jenefer M Blackwell; Matthew A Brown; Aiden P Corvin; Mark I McCarthy; Chris C A Spencer; Elvira Bramon; Aiden P Corvin; Michael C O'Donovan; Kari Stefansson; Edward Scolnick; Shaun Purcell; Steven A McCarroll; Pamela Sklar; Christina M Hultman; Patrick F Sullivan
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more
  38 in total

1.  SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse.

Authors:  Frank Koopmans; Pim van Nierop; Maria Andres-Alonso; Andrea Byrnes; Tony Cijsouw; Marcelo P Coba; L Niels Cornelisse; Ryan J Farrell; Hana L Goldschmidt; Daniel P Howrigan; Natasha K Hussain; Cordelia Imig; Arthur P H de Jong; Hwajin Jung; Mahdokht Kohansalnodehi; Barbara Kramarz; Noa Lipstein; Ruth C Lovering; Harold MacGillavry; Vittoria Mariano; Huaiyu Mi; Momchil Ninov; David Osumi-Sutherland; Rainer Pielot; Karl-Heinz Smalla; Haiming Tang; Katherine Tashman; Ruud F G Toonen; Chiara Verpelli; Rita Reig-Viader; Kyoko Watanabe; Jan van Weering; Tilmann Achsel; Ghazaleh Ashrafi; Nimra Asi; Tyler C Brown; Pietro De Camilli; Marc Feuermann; Rebecca E Foulger; Pascale Gaudet; Anoushka Joglekar; Alexandros Kanellopoulos; Robert Malenka; Roger A Nicoll; Camila Pulido; Jaime de Juan-Sanz; Morgan Sheng; Thomas C Südhof; Hagen U Tilgner; Claudia Bagni; Àlex Bayés; Thomas Biederer; Nils Brose; John Jia En Chua; Daniela C Dieterich; Eckart D Gundelfinger; Casper Hoogenraad; Richard L Huganir; Reinhard Jahn; Pascal S Kaeser; Eunjoon Kim; Michael R Kreutz; Peter S McPherson; Ben M Neale; Vincent O'Connor; Danielle Posthuma; Timothy A Ryan; Carlo Sala; Guoping Feng; Steven E Hyman; Paul D Thomas; August B Smit; Matthijs Verhage
Journal:  Neuron       Date:  2019-06-03       Impact factor: 17.173

2.  Power Analysis for Genetic Association Test (PAGEANT) provides insights to challenges for rare variant association studies.

Authors:  Andriy Derkach; Haoyu Zhang; Nilanjan Chatterjee
Journal:  Bioinformatics       Date:  2018-05-01       Impact factor: 6.937

3.  Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals.

Authors: 
Journal:  Am J Hum Genet       Date:  2019-07-18       Impact factor: 11.025

4.  Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease.

Authors:  Seyedeh M Zekavat; Krishna Aragam; Connor Emdin; Amit V Khera; Derek Klarin; Hongyu Zhao; Pradeep Natarajan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06       Impact factor: 8.311

5.  Truncating variant burden in high-functioning autism and pleiotropic effects of LRP1 across psychiatric phenotypes

Authors:  Bàrbara Torrico; Alex D. Shaw; Roberto Mosca; Norma Vivó-Luque; Amaia Hervás; Noèlia Fernàndez-Castillo; Patrick Aloy; Mònica Bayés; Janice M. Fullerton; Bru Cormand; Claudio Toma
Journal:  J Psychiatry Neurosci       Date:  2019-09-01       Impact factor: 6.186

Review 6.  Cognitive Genomics: Recent Advances and Current Challenges.

Authors:  Joan Fitzgerald; Derek W Morris; Gary Donohoe
Journal:  Curr Psychiatry Rep       Date:  2020-01-10       Impact factor: 5.285

7.  Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation.

Authors:  Seung Hoan Choi; Lu-Chen Weng; Carolina Roselli; Honghuang Lin; Christopher M Haggerty; M Benjamin Shoemaker; John Barnard; Dan E Arking; Daniel I Chasman; Christine M Albert; Mark Chaffin; Nathan R Tucker; Jonathan D Smith; Namrata Gupta; Stacey Gabriel; Lauren Margolin; Marisa A Shea; Christian M Shaffer; Zachary T Yoneda; Eric Boerwinkle; Nicholas L Smith; Edwin K Silverman; Susan Redline; Ramachandran S Vasan; Esteban G Burchard; Stephanie M Gogarten; Cecelia Laurie; Thomas W Blackwell; Gonçalo Abecasis; David J Carey; Brandon K Fornwalt; Diane T Smelser; Aris Baras; Frederick E Dewey; Cashell E Jaquish; George J Papanicolaou; Nona Sotoodehnia; David R Van Wagoner; Bruce M Psaty; Sekar Kathiresan; Dawood Darbar; Alvaro Alonso; Susan R Heckbert; Mina K Chung; Dan M Roden; Emelia J Benjamin; Michael F Murray; Kathryn L Lunetta; Steven A Lubitz; Patrick T Ellinor
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

8.  Common genetic variants contribute to risk of rare severe neurodevelopmental disorders.

Authors:  Mari E K Niemi; Hilary C Martin; Daniel L Rice; Giuseppe Gallone; Scott Gordon; Martin Kelemen; Kerrie McAloney; Jeremy McRae; Elizabeth J Radford; Sui Yu; Jozef Gecz; Nicholas G Martin; Caroline F Wright; David R Fitzpatrick; Helen V Firth; Matthew E Hurles; Jeffrey C Barrett
Journal:  Nature       Date:  2018-09-26       Impact factor: 49.962

Review 9.  A framework for the investigation of rare genetic disorders in neuropsychiatry.

Authors:  Stephan J Sanders; Mustafa Sahin; Joseph Hostyk; Audrey Thurm; Sebastien Jacquemont; Paul Avillach; Elise Douard; Christa L Martin; Meera E Modi; Andres Moreno-De-Luca; Armin Raznahan; Alan Anticevic; Ricardo Dolmetsch; Guoping Feng; Daniel H Geschwind; David C Glahn; David B Goldstein; David H Ledbetter; Jennifer G Mulle; Sergiu P Pasca; Rodney Samaco; Jonathan Sebat; Anne Pariser; Thomas Lehner; Raquel E Gur; Carrie E Bearden
Journal:  Nat Med       Date:  2019-09-23       Impact factor: 53.440

10.  Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure.

Authors:  Mary E Haas; Krishna G Aragam; Connor A Emdin; Alexander G Bick; Gibran Hemani; George Davey Smith; Sekar Kathiresan
Journal:  Am J Hum Genet       Date:  2018-09-13       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.